• Systemic sclerosis (scleroderma)
• Rheumatoid arthritis
• Sjögren's disease
• Inflammatory myositis (such as antisynthetase syndrome).
Still in early trials. While 12 TCEs are already approved for cancer,
• Systemic sclerosis (scleroderma)
• Rheumatoid arthritis
• Sjögren's disease
• Inflammatory myositis (such as antisynthetase syndrome).
Still in early trials. While 12 TCEs are already approved for cancer,
TCEs are bispecific antibodies built with two binding arms: one attaches to a surface protein on a patient’s T cells (usually CD3), while the other binds to a marker on disease-driving B cells (such as CD19 or BCMA). By physically linking the two cells together
TCEs are bispecific antibodies built with two binding arms: one attaches to a surface protein on a patient’s T cells (usually CD3), while the other binds to a marker on disease-driving B cells (such as CD19 or BCMA). By physically linking the two cells together
www.nature.com/articles/s41... and ongoing Phase 1 clinical trials are testing TCEs across a wide range of #Bcell driven #autoimmunedisorders:
www.nature.com/articles/s41... and ongoing Phase 1 clinical trials are testing TCEs across a wide range of #Bcell driven #autoimmunedisorders:
Relatório aponta desvio de finalidade em recursos destinados à infraestrutura e aplicados na Expofar de 2024
jornalggn.com.br/justica-2/tc...
pharmaphorum.com/news/boehrin...
pharmaphorum.com/news/boehrin...
#prisao #presidente #TribunalDeContas #MatoGrosso #corrupcao
#prisao #presidente #TribunalDeContas #MatoGrosso #corrupcao
Tem muita coisa pra mudar e melhorar. Se deixar pra direita, fodeu.
Tem muita coisa pra mudar e melhorar. Se deixar pra direita, fodeu.
iclnoticias.com.br/entenda-esqu...
iclnoticias.com.br/entenda-esqu...
🔗 Source: https://pubmed.ncbi.nlm.nih.gov/42921550/
🔗 Source: https://pubmed.ncbi.nlm.nih.gov/42921550/
👉 www.genoway.com/fr/news-even...
👉 www.genoway.com/fr/news-even...
Read more: tinyurl.com/355vyu77
#PreclinicalResearch #NAMs #ADCs #TCEs
Read more: tinyurl.com/355vyu77
#PreclinicalResearch #NAMs #ADCs #TCEs
TD22 slipped $750k to $51.19m, with TCEs at $394k/day. Activity remains quiet, with no fresh fixtures reported.
TD22 slipped $750k to $51.19m, with TCEs at $394k/day. Activity remains quiet, with no fresh fixtures reported.
TC12 jumped 6.56 pts to WS388.75, pushing TCEs to $40,228/day, while TC17 climbed 15 pts to WS820, with TCEs at $102,904/day, up $2,350/day.
TC12 jumped 6.56 pts to WS388.75, pushing TCEs to $40,228/day, while TC17 climbed 15 pts to WS820, with TCEs at $102,904/day, up $2,350/day.